Cat. No. 4478
Chemical Name: 4-[[3,5-Bis(trifluoromethyl)phenyl]
Biological ActivityGPBA receptor agonist. Upregulates GLP-1 secretion from intestinal cultures. Increases MQAE-fluorescence suggesting a decrease in intracellular chloride concentration in gallbladder epithelial cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Parker et al (2012) Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br.J.Pharmacol. 165 414. PMID: 21718300.
Keitel et al (2009) The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50 861. PMID: 19582812.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for GPBAR-A include:
Kowal et al (2015) Bile acid effects are mediated by ATP release and purinergic signalling in exocrine pancreatic cells. Stem Cells Transl Med 13 28. PMID: 26050734.
Do you know of a great paper that uses GPBAR-A from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GPBAR-A, supplier, TGR5, agonists, g-protein, bile, acid, receptors, GPBA, GPBAR, Tocris Bioscience, GPBA Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
October 30 - November 3, 2016
Boston, MA, USA